Department of Surgery, 16436University Hospital Fundación Jiménez Díaz, Madrid, Spain.
New Therapies Laboratory, 218187Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Surg Innov. 2022 Feb;29(1):9-21. doi: 10.1177/15533506211013142. Epub 2021 Apr 30.
The aims of this study are to compare 2 origins of adipose-derived mesenchymal stem cells (MSCs) (omentum and subcutaneous) from 2 pathologies (morbid obesity and cancer) vs healthy donors. Adipose tissue has revealed to be the ideal MSC source. However, in developing adipose-derived stem cells (ASCs) for clinical use, it is important to consider the effects of different fat depots and also the effect of donor variability. We isolated and characterized the membrane markers and differentiation capacities of ASCs obtained from patients with these diseases and different origin. During the culture period, we further analysed the cells' proliferation capacity in an in vitro assay as well as their secretome. Adipose-derived stem cells isolated from obese and cancer patients have mesenchymal phenotype and similar cell proliferation as ASCs derived from healthy donors, some higher in cells derived from subcutaneous fat. However, cells from these 2 types of patients do not have the same differentiation potential, especially in cancer patients from omentum, and exhibit distinct secretion of both pro-inflammatory and regulatory cytokines, which could explain the differences in use due to origin as well as pathology associated with the donor. Subcutaneous and omentum ASCs are slightly different; omentum generates fewer cells but with greater anti-inflammatory capacity. Adipose-derived stem cells from patients with either obesity or cancer are slightly altered, which limits their therapeutic properties.
本研究旨在比较来源于两种病变(病态肥胖和癌症)和健康供体的两种脂肪来源间充质干细胞(MSCs)(大网膜和皮下)。脂肪组织已被证明是 MSC 的理想来源。然而,在开发用于临床的脂肪源性干细胞(ASCs)时,重要的是要考虑不同脂肪沉积的影响,以及供体变异性的影响。我们分离并鉴定了来源于这些疾病和不同来源的患者的 ASC 的膜标记物和分化能力。在培养期间,我们进一步在体外分析了细胞的增殖能力及其分泌组。从肥胖和癌症患者中分离的脂肪源性干细胞具有间充质表型,其增殖能力与健康供体来源的 ASC 相似,有些细胞来自皮下脂肪的增殖能力更高。然而,这两种类型的患者的细胞没有相同的分化潜力,尤其是大网膜来源于癌症患者的细胞,并且表现出不同的促炎和调节细胞因子的分泌,这可以解释由于起源以及与供体相关的病理学导致的用途差异。皮下和大网膜 ASC 略有不同;大网膜产生的细胞较少,但具有更强的抗炎能力。肥胖或癌症患者的脂肪源性干细胞略有改变,这限制了它们的治疗特性。